Poitiers

• A phase 3, open-label, controlled, randomized study of newly diagnosed multiple myeloma treatment, designed to evaluate the efficacy and saf … Recruiting
  2024-516418-39-00 5 2025-07-09 Multiple Myeloma
• A study to evaluate the efficacy of APG-2575 (Lisaftoclax) plus azacitidine (AZA) vs. placebo plus AZA in newly diagnosed adult subjects wit … Recruiting
  2024-517247-31-00 5 2025-07-07 Newly Diagnosed Higher Risk Myelodysplastic Syndrome
• An Open-Label, Phase 2 Study to Evaluate Safety, Tolerability and Preliminary Activity of the CTPS1 Inhibitor STP938 in Adult Subjects with … Recruiting
  2024-519964-42-00 4 2025-07-02 Thrombocythaemia
• A study to understand if sotagliflozin improves symptoms and is safe in people with hypertrophic cardiomyopathy Recruiting
  2024-513869-39-00 5 2025-06-27 Obstructive Cardiomyopathy, Hypertrophic
• ​​Master Protocol of Novel Study Interventions and Combinations in Participants with Colorectal Cancer​ Recruiting
  2024-518469-84-00 4 2025-06-20 ​​Colorectal cancer​
• IFM2024-06 : A multi-center, open-label, phase 2 randomized study of elranatamab plus lenalidomide versus daratumumab plus lenalidomide as p … Recruiting
  2024-517325-43-00 4 2025-06-19 multiple myeloma
• Evaluation of 200 mg of Rituximab every 6 months as maintenance treatment of Rituximab-treated patients with rheumatoid arthritis: a non-inf … Recruiting
  2024-519991-18-00 6 2025-06-16 Rheumatoid Arthritis
• A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration ( … Recruiting
  2023-510294-34-00 5 2025-06-12 small lymphocytic lymphoma (SLL)
• A clinical study to assess the safety and efficacy of oral ART0380 as a single agent or in combination in solid tumors Recruiting
  2024-511534-12-00 7 2025-06-10 Advanced or Metastatic Solid Tumours
• Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab versus Chemotherapy Plus Trastuzumab Plus or Minus … Recruiting
  2024-513122-27-00 5 2025-06-10 Unresectable, Locally Advanced or Metastatic HER2 positive Gastric or
• Intra-arterial thrombolysis after SUCCESSful reperfusion of acute ischemic stroke Recruiting
  2023-506935-14-01 5 2025-06-01 Ischemic stroke
• An open-label extension study to assess the efficacy and safety of ianalumab with or without study treatment withdrawal in adult participan … Recruiting
  2024-515280-60-00 5 2025-05-29 Lupus nephritis
• ATLANTIS Protamine - Antagonization of heparin with protamine sulfate to reduce all neurologic ischemic and hemorrhagic events after transca … Recruiting
  2023-504511-32-00 5 2025-05-24 Any patients ≥18 years old, eligible for transfemoral TAVI with covera
• A study Investigating Subcutaneously Administered Pozelimab in Combination with Cemdisiran or Cemdisiran Alone in Adult Participants with Ge … Recruiting
  2023-509547-27-00 5 2025-05-22 Geographic Atrophy Secondary to Age-Related Macular Degeneration
• Efficacy of daily IV administration of dornase alfa for up to 14 days post subarachnoid haemorrhage on functional independence at 6 months: … Recruiting
  2023-509627-40-01 5 2025-05-15 subarachnoid hemorrhage
• A trial to learn how well baxdrostat with dapagliflozin works compared to dapagliflozin on clinical outcomes alone and how safe it is in adu … Recruiting
  2023-506460-14-00 5 2025-05-07 Chronic kidney disease (CKD) and hypertension.
• Is CT 01 safe to use alone or combined with Everolimus for inoperable advanced liver cancer? Recruiting
  2024-511435-10-00 1 2025-04-30 Hepatocellular Carcinoma
• A study of elritercept to treat transfusion-dependent anemia due to very low, low, or intermediate risk myelodysplastic syndromes Recruiting
  2024-516009-22-00 5 2025-04-30 myelodysplastic neoplasms/syndromes (MDS)
• Randomized clinical trial to compare oral isotretinoin to standard of care in moderate acne skin of color patients Recruiting
  2023-507519-36-00 5 2025-04-29 Acne
• A study to assess the effectiveness and safety of pacritinib in patients with VEXAS syndrome (PAXIS) Recruiting
  2024-516347-41-00 4 2025-04-29 VEXAS Syndrome
• Evaluation of the benefits of Administering immunosuppressive drugs as Single daily doses over the first Year after liver transplantation Recruiting
  2023-506601-19-00 6 2025-04-15 transplantation
• Best hypnotic drug choice for rapid sequence induction in the operating room: a 3-arm randomized trial open-labelled with blinded evaluation … Recruiting
  2024-517582-16-00 5 2025-04-14 rapid sequence induction in the operating room
• A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T cells (CABA-201) i … Recruiting
  2023-507613-10-01 7 2025-03-31 Active Systemic Lupus Erythematosus;Systemic lupus erythematosus (SLE)
• Efficacy and safety of bezafibrate 400 mg and bezafibrate 200 mg as adjunctive treatments in patients with primary biliary cholangitis and n … Recruiting
  2023-504086-23-00 5 2025-03-27 Subjects with PBC with a non-optimal response to UDCA.

Showing 169–192 of 615 trials